clinical trial · NCT05866432
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Medical University of Vienna·phase2·active not recruiting·n = 20
Breast Cancer Stage IVDatopotamab deruxtecan
brief summary
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
started
Jul 1, 2023
primary completion
Jul 1, 2026
completion
Jul 1, 2027
last updated
Oct 30, 2026
detailed description
Datopotamab-deruxtecan will be administered at a dose of 6.0 mg/kg body weight i.v. on day
1 once every three weeks in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases. Response rate by RANO-BM criteria is definied as primary endpoint.
official title
Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol